| 3.58 0.01 (0.28%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.96 | 1-year : | 8.13 |
| Resists | First : | 5.95 | Second : | 6.96 |
| Pivot price | 2.34  |
|||
| Supports | First : | 2.84 | Second : | 0.92 |
| MAs | MA(5) : | 2.74 |
MA(20) : | 2.09 |
| MA(100) : | 2.11 |
MA(250) : | 3.98 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 45.2 |
D(3) : | 35.1 |
| RSI | RSI(14): 60.4 |
|||
| 52-week | High : | 19.9 | Low : | 0.92 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ INDP ] has closed below upper band by 20.2%. Bollinger Bands are 191.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.86 - 3.87 | 3.87 - 3.89 |
| Low: | 3.17 - 3.18 | 3.18 - 3.2 |
| Close: | 3.56 - 3.58 | 3.58 - 3.61 |
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
Sat, 06 Jun 2026
Indaptus Therapeutics, Inc. Files Form 8-K Announcing CEO Change – Junyi Dai Appointed CEO - Minichart
Fri, 05 Jun 2026
Leadership shifts at Indaptus Therapeutics (NASDAQ: INDP) as directors and COO exit - Stock Titan
Thu, 04 Jun 2026
Indaptus Therapeutics (INDP) Jumps 53.8% Amid Heavy Volume as Investors Focus on Financing/strategic-option Uncertainty - Moomoo
Thu, 04 Jun 2026
Indaptus Therapeutics (INDP) jumps 53.8% amid heavy volume as investors focus on financing/strategic-option uncertainty - Quiver Quantitative
Fri, 15 May 2026
Indaptus Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Fri, 15 May 2026
Biotech Indaptus ends Q1 with $1.5M cash, weighs next steps - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 113 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 60 (K) |
| Shares Short P.Month | 53 (K) |
| EPS | -12.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -286.9 % |
| Return on Equity (ttm) | -931.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.29 |
| PEG Ratio | 0 |
| Price to Book value | 358 |
| Price to Sales | 0 |
| Price to Cash Flow | -24.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|